Recent Updates — GLPGF
Lakefront Biotherapeutics NV completed its share repurchase program announced on June 9, 2026, by purchasing 107,804 shares between October 12 and October 16, 2026. The company spent a total of €2,854,365.69 at an average price of €26.48 per share across multiple European exchanges. As of market close on October 16, Lakefront holds 1,985,157 of its own ordinary shares. The filing discloses the final execution details of this discretionary mandate to an independent financial intermediary. Lakefront Biotherapeutics is a clinical-stage biotechnology company developing immunology and inflammation treatments.
Lakefront Biotherapeutics announced that the U.S. FDA granted Orphan Drug Designation for gamgertamig to treat pemphigus. The company also noted that gamgertamig, developed in collaboration with Gilead Sciences and licensed from Keymed Biosciences, previously received Fast Track and Orphan Drug Designations for autoimmune hemolytic anemia (AIHA) and immune thrombocytopenia (ITP). Ongoing Phase 1b trials are active in Australia, the United States, New Zealand, the Czech Republic, and Japan. The company anticipates expanding its clinical program with proof-of-concept basket studies in 2027 as it advances toward registrational studies for this BCMAxCD3 bispecific T cell engager. Lakefront Biotherapeutics is a biotechnology company developing immunology and inflammation treatments.
Lakefront Biotherapeutics NV received a transparency notification from Bank of America Corporation indicating that the financial institution crossed the 10% voting rights threshold in the company on August 18, 2026. As of August 19, 2026, Bank of America and its affiliates held 1,419,144 direct voting rights and 5,243,453 equivalent financial instruments, representing a total of 10.11% of the company's 65,897,071 outstanding shares. The position includes significant holdings in swaps and rights to use securities across various expiration dates through 2028. Lakefront Biotherapeutics is a biotechnology company developing clinical-stage medicines for immunology and inflammation.